Tempest Therapeutics Inc TPST

US Biotechnology

$0.83 ▼ -2.47% ($-0.02)

⬇️ Below Yest. Low

Open $0.87

Prev Close $0.85

Day Range $0.82 – $0.89

52W Range $0.74 – $12.23

Market Cap $13.25M

Beta -1.58

EPS (TTM) $-4.49

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2012-10-04
Shares Out.	15,980,000
Website	tempesttx.com/ ↗
Phone	13026587581
Employees	4
Revenue	$0
Gross Profit	$0
Net Income	-$5.2M
Free Cash Flow	-$20.7M
Total Assets	$9.6M
Total Liabilities	$10.7M
Equity	-$1.1M

About Tempest Therapeutics Inc

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Tempest Therapeutics Inc is a publicly traded company under the ticker symbol TPST on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.